Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy;Monoaminerge funktion bei depressiven patienten. Eine hilfe bei der wahl der behandlungsstrategie?

Nervenarzt

Volumn 77, Issue 7, 2006, Pages 800-808

  Moeller, O ^a   Norra, C ^a   Grunder G ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Dopamine; Major Depression; Noradrenaline; Response; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HYDROCORTISONE; MELATONIN; MONOAMINE; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PROLACTIN; REBOXETINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

DRUG CHOICE; DRUG RESPONSE; EMOTIONAL STRESS; EVOKED RESPONSE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NEUROENDOCRINE SYSTEM; NEUROIMAGING; NORADRENERGIC SYSTEM; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BIOLOGICAL MARKERS; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; NOREPINEPHRINE; PROGNOSIS; TREATMENT OUTCOME;

EID: 33745754961     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-2042-2     Document Type: Review

References (60)

1. Arias B, Catalan R, Gasto C et al. (2003) 5-HHLPR Polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with Citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23: 563-567
2. Attar-Levy D, Martinet JL, Blin J et al. (1999) The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 45: 180-186
3. Charney DS (1998) Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 59: 11-14
4. Correa H, Duval F, Claude MM et al. (2001) Noradrenergic dysfunction and antidepressant treatment response. Eur Neuropsychopharmacol 11: 163-168
5. Delgado PL, Charney DS, Price LH et al. (1990) Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47: 411-418
6. Durham LK, Webb SM, Milos PM et al. (2004) The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 174: 525-529
7. Gallinat J, Bottlender R, Juckel G et al. (2000) The loudness dependency of the auditory-evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl) 148: 404-411
8. Goodwin GM, Green AR, Johnson P (1984) 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol 83: 235-242
9. Hegerl U, Gallinat J, Juckel G (2001) Event-related potentials: do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62: 93-100
10. Heninger GR, Delgado PL, Charney DS (1996) The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29: 2-11
11. Hetzel G, Moeller O, Erfurth A et al. (2004) The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry 37: 200-205
12. Himani A, Tandon OP, Bhatia MS (1999) A study of P300-event related evoked potential in the patients of major depression. Indian J Physiol Pharmacol 43: 367-372
13. Ito K, Yoshida K, Sato K et al. (2002) A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111: 235-239
14. Johnston TG, Kelly CB, Stevenson MR et al. (1999) Plasma norepinephrine and prediction of outcome in major depressive disorder. Biol Psychiatry 46: 1253-1258
15. Juckel G, Mavrogiorgou P, Bredemeier S et al. (2004) Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders - A retrospective study. Pharmacopsychiatry 37: 46-51
16. Kapitany T,Schindl M, Schindler SD (1999) The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res 88: 75-88
17. Kegeles LS, Malone KM, Slifstein M et al. (2003) Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. Am J Psychiatry 160: 76-82
18. Klimke A, Larisch R, Janz A et al. (1999) Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 90: 91-101
19. Kugaya A, Sanacora G, Staley JK et al. (2004) Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 56: 497-502
20. Laakmann G, Schoen HW, Blaschke D et al. (1985) Dose-dependend growth hormone, prolactin and cortisol stimulation after i. v.-administration of desipramine. Psychoneuroendocinology 10: 83-93
21. Leonard BE (1997) Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 7: 11-16
22. Lesch KP, Laux G, Schulte HM et al. (1988) Pre- and postsynaptic alpha-adrenergic effects of clonidine in major depressive disorder. Pharmacopsychiatry 21: 430-431
23. Linka T, Muller BW, Bender S et al. (2004) The intensity dependence of the auditory evoked N1 component as a predictor of response to citalopram treatment in patients with major depression. Neurosci Lett 367: 375-378
24. Lucini V, Lucca A, Catalano M et al. (1996) Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. J Affect Disord 36: 129-133
25. Meltzer CC, Price JC, Mathis CA et al. (2004) Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 29: 2258-2265
26. Meyer JH, Kapur S, Eisfeld B et al. (2001) The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158: 78-85
27. Meyer JH, Wilson AA, Ginovart N et al. (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849
28. Miller HL, Ekstrom RD, Mason GA et al. (2001) Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology 24: 617-623
29. Mischoulon D, Dougherty DD, Bottonari KA et al. (2002) An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Res 116: 151-161
30. Möller HJ (2004) Therapieresistenz auf Antidepressiva. Definition, Häufigkeit, Prädiktoren und Interventions-Möglichkeiten. Nervenarzt 75: 499-515
31. Moeller O, Hetzel G, Michael N et al. (2005) Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram. Neuropsychobiology 51: 67-71
32. Moeller O, Hetzel G, Rothermundt M et al. (2003) Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment. J Psychiatr Res 37: 261-262
33. Moller SE (1990) 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients. Eur Neuropsychopharmacol 1: 41-44
34. Moresco RM, Colombo C, Fazio F et al. (2000) Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage 12:452-465
35. New AS, Woo-Ming A, Mitropoulou V et al. (1999) Serotonin and the prediction of response time to fluoxetine in patients with mild depression. Psychiatry Res 88: 89-93
36. Newman ME, Shapira B, Lerer B (1998) Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int J Neuropsychopharmacol 1: 49-69
37. O'Keane V, Dinan TG (1991) Prolactin and cortisol responses to d-fenfluramin in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 148: 1009-1015
38. Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40: 288-295
39. Paige SR, Fitzpatrick DF, Kline JP et al. (1994) Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 30: 197-201
40. Paige SR, Hendricks SE, Fitzpatrick DF et al. (1995) Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull 31: 243-248
41. Perez V, Bel N, Celada P et al. (1998) Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. J Clin Psychopharmacol 18: 222-230
42. Pollock BG, Ferrell RE, Mulsant BH et al. (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23: 587-590
43. Porter RJ, Mulder RT, Joyce PR (2003) Baseline prolactin and L-tryptophan availability predict response to antidepressant treatment in major depression. Psychopharmacology (Berl) 165: 216-221
44. Sargent PA, Kjaer KH, Bench CJ et al. (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180
45. Sato K, Yoshida K, Takahashi H et al. (2002) Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 46: 136-140
46. Schatzberg AF (1998) Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J Clin Psychiatry 59: 15-18
47. Schule C, Baghai T, Schmidbauer S et al. (2004) Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 29: 185-200
48. Seretti A, Zanardi R, Rossini D et al. (2001) Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 6: 586-592
49. Shinkai K, Yoshimura R, Ueda N et al. (2004) Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24: 11-17
50. Smeraldi E, Zanardi R, Benedetti F et al. (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3: 508-511
51. Szegedi A, Rujescu D, Tadic A et al. (2005) The catechol-O- methyltransferase Val(108/158)Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5: 49-53
52. Ueda N, Yoshimura R, Shinkai K et al. (2002) Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35: 175-181
53. Vandoolaeghe E, van Hunsel F, Nuyten D et al. (1998) Auditory event related potentials in major depression: prolonged P300 latency and increased P200 amplitude. J Affect Disord 48: 105-113
54. Weizman A, Weizman R (2000) Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1: 335-341
55. Wilson AA, Johnson DP, Mozley D et al. (2003) Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 30: 85-92
56. Yatham LN, Liddle PF, Dennie J et al. (1999) Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 56: 705-711
57. Yoshida K, Takahashi H, Higuchi H et al. (2004) Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161: 1575-1580
58. Yu YW, Tsai SJ, Chen TJ et al. (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 7: 1115-1119
59. Zill P, Baghai TC, Engel R et al. (2003) Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response. Am J Med Genet 120: 85-89
60. Zill P, Baghai TC, Zwanzger P et al. (2000) Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 11: 1893-1897